What are the treatment options for irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD)?

Treatment of Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD)

IBS and IBD are fundamentally different diseases requiring distinct treatment approaches: IBS is a disorder of gut-brain interaction managed with lifestyle modifications, neuromodulators, and psychological therapies, while IBD is an inflammatory condition requiring anti-inflammatory medications, immunomodulators, and biologics. 1

Understanding the Critical Distinction

These conditions share overlapping symptoms (abdominal pain, altered bowel habits) but differ completely in pathophysiology, natural history, and treatment 2. IBS is not a prodromal form of IBD, nor are they part of the same disease spectrum 2. The limited symptom repertoire of the gastrointestinal tract creates apparent confusion, but their divergent treatment paths make this distinction clinically essential 2.

Key Diagnostic Pitfall

When an IBD patient in apparent remission reports IBS-type symptoms, measure fecal calprotectin to detect subclinical inflammation before attributing symptoms to coincident IBS 2. This prevents both undertreatment of active IBD and overtreatment with immunosuppression when true functional symptoms are present 1.

---

Treatment Algorithm for IBS

First-Line Management (All IBS Subtypes)

Begin with patient education explaining IBS as a gut-brain interaction disorder, emphasizing the benign prognosis and relapsing-remitting course 3. Discuss how stress aggravates symptoms and impairs coping, and explain the concept of a sensitive, hyperactive gut 3.

Lifestyle Modifications

• Recommend regular physical exercise to all IBS patients as foundational therapy 1
• Establish regular times for defecation 3
• Maintain adequate sleep hygiene 3

Dietary Interventions

• Start soluble fiber (ispaghula/psyllium) at 3-4 g/day, gradually increasing to avoid bloating 1
• Avoid insoluble fiber (wheat bran) as it consistently worsens symptoms 1
• Identify and reduce excessive intake of lactose, fructose, sorbitol, caffeine, or alcohol in diarrhea-predominant patients 3
• Do NOT recommend gluten-free diets unless celiac disease is confirmed 1
• Do NOT use IgG antibody-based food elimination diets 1

Probiotics

• Consider a 12-week trial of probiotics for global symptoms and abdominal pain; discontinue if no improvement 1

Symptom-Specific Pharmacological Treatment

For IBS with Diarrhea (IBS-D)

• Loperamide 4-12 mg daily (either regularly or prophylactically before going out) as first-line antidiarrheal 3
• 5-HT3 receptor antagonists (e.g., ondansetron) are highly efficacious second-line drugs 1
• Rifaximin (non-absorbable antibiotic) is effective for IBS-D, though its effect on abdominal pain is limited 1
• Cholestyramine may benefit a small number with bile acid malabsorption but is often less well tolerated than loperamide 3

For IBS with Constipation (IBS-C)

• Start polyethylene glycol (PEG) as first-line osmotic laxative, titrating dose according to symptoms 4
• If PEG fails after 4-6 weeks, add bisacodyl 10-15 mg once daily, titrating up to three times daily if needed 4
• Linaclotide 290 mcg once daily on an empty stomach is the preferred second-line prescription agent when laxatives fail 1, 4
• Lubiprostone 8 mcg twice daily is an alternative if linaclotide is not tolerated, though nausea is common 1
• AVOID anticholinergic antispasmodics (like dicyclomine) in IBS-C as they worsen constipation 4

For Abdominal Pain (All Subtypes)

• Antispasmodics with anticholinergic properties (dicyclomine 40 mg four times daily) are effective for pain, particularly when exacerbated by meals 3, 5
• Peppermint oil can be useful as an antispasmodic 3, 4

Second-Line Treatment: Neuromodulators

When first-line therapies fail after 3 months, tricyclic antidepressants (TCAs) are the most effective second-line drugs for global symptoms and abdominal pain 1:

• Start amitriptyline 10 mg once daily at bedtime, titrating slowly (by 10 mg/week) to 30-50 mg daily 1, 4
• Continue for at least 6 months if symptomatic response occurs 4
• Explain the rationale clearly: TCAs work by modulating pain perception and gut-brain signaling, not as antidepressants at these doses 1
• In IBS-C, use TCAs cautiously and ensure adequate laxative therapy is in place, as they may worsen constipation 1, 4

Selective serotonin reuptake inhibitors (SSRIs) are effective alternatives when TCAs are not tolerated or worsen constipation 1, 4.

Third-Line Treatment: Psychological Therapies

When symptoms persist despite 12 months of pharmacological treatment, offer cognitive-behavioral therapy (CBT) specific for IBS or gut-directed hypnotherapy 1, 4:

• These therapies are particularly effective for patients who relate symptom exacerbations to stressors or have associated anxiety/depression 4
• Dynamic psychotherapy benefits patients with symptoms of relatively short duration 4
• Simple relaxation therapy using audiotapes can be tried initially 3

Critical IBS Management Pitfalls

• Never use opiates for chronic pain management in IBS due to risks of dependence and complications 1, 4
• Review treatment efficacy after 3 months and discontinue if no response 4
• Avoid extensive testing once diagnosis is established using Rome criteria without alarm features 3
• Recognize that complete symptom resolution is often not achievable; the goal is symptom relief and improved quality of life 4

---

Treatment Algorithm for Inflammatory Bowel Disease (IBD)

Mild to Moderate Ulcerative Colitis

5-aminosalicylates (5-ASAs) are first-line anti-inflammatory medications for mild to moderate UC 1:

• These directly target intestinal inflammation, unlike IBS treatments which modulate symptoms 1

Moderate to Severe UC or Flares

Corticosteroids are indicated for moderate to severe flares 1:

• Use for acute disease control, not long-term maintenance due to side effects 1

Maintenance Therapy and Refractory Disease

• Immunomodulators are used for maintenance therapy 1
• Biologics (anti-TNF agents, anti-integrins, JAK inhibitors) are effective for moderate to severe UC or steroid-dependent cases 1

Managing IBS-Type Symptoms in IBD Patients

When an IBD patient in remission reports persistent IBS-type symptoms:

1. First, measure fecal calprotectin to exclude subclinical inflammation 2
2. If calprotectin is elevated, intensify IBD-directed therapy 2
3. If calprotectin is normal and inflammation is truly absent:
   • Tricyclic antidepressants have shown benefit for functional GI symptoms in IBD patients 1
   • Rifaximin may be beneficial if small intestinal bacterial overgrowth (SIBO) is suspected 1
   • Consider IBS-directed therapies (dietary modifications, neuromodulators, psychological therapies) 1

Critical IBD Management Pitfall

Never attribute persistent symptoms in IBD to coincident IBS without first excluding ongoing inflammation with objective measures (calprotectin, endoscopy, imaging) 2. The consequences of undertreating active IBD (strictures, fistulas, cancer risk) far outweigh the risks of additional investigation 2.

---

When to Suspect One Condition vs. The Other

Favor IBS Diagnosis When:

• Symptoms meet Rome criteria (recurrent abdominal pain ≥1 day/week for 3 months, related to defecation, associated with change in stool frequency or form) 6
• Normal inflammatory markers (CRP, ESR) 7
• Normal fecal calprotectin 7
• No alarm features (rectal bleeding, unintentional weight loss, nocturnal symptoms, family history of IBD/colon cancer, age >50 with new symptoms) 3

Favor IBD Diagnosis When:

• Persistent bloody diarrhea 2
• Elevated inflammatory markers 7
• Elevated fecal calprotectin 7
• Endoscopic evidence of mucosal inflammation 2
• Extraintestinal manifestations (arthritis, uveitis, erythema nodosum) 2

The presence of alarm features mandates endoscopic evaluation before attributing symptoms to IBS 3, 7.